Integra Misled Investors on Response to FDA Warning, Suit Says

Integra LifeSciences Holdings Corp. and its top executives allegedly misrepresented improvements it had made to its Boston manufacturing plant before its stock’s biggest selloff since in more than two decades, a shareholder suit says.

The medical device manufacturer allegedly told investors it was making improvements to the Boston facility for more than four years after a Food and Drug Administration letter highlighting inadequate testing for dangerous toxins, but did not take necessary steps to mitigate those risks before ultimately halting production at that facility.

After Integra revealed the manufacturing stoppage and resulting negative impacts on operating margins and growth projections, ...